Comparison of ARX788 and Lapatinib/Capecitabine in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer

Conference Correspondent  - SABCS Highlights

A novel antibody–drug conjugate that consists of a human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibody site-specifically conjugated with payload AS269 (Amberstatin), a highly potent tubulin inhibitor, is currently being investigated.

In heavily pretreated patients who had received a median of 5 previous treatment regimens and had HER2-positive metastatic breast cancer, promising results were shown from a phase 1 study, in cohorts dosing from 1.1 mg/kg to 1.5 mg/kg antitumor activity was shown with an objective response rate of 52.0%.

Among the patients who had received tyrosine kinase inhibitor treatment previously, the objective response rate was 48.5%. In the 1.5-mg/kg every-3-weeks cohort, the objective response rate was 68.4% and the median progression-free survival was not reached; this was because the majority of subjects were still receiving ARX788 treatment.

Xichun Hu, MD, PhD, Professor, Medical Oncology, Shanghai Cancer Center, Fudan University Shanghai Cancer Center, China, and colleagues provided an overview of a phase 2/3 study evaluating patients with HER2-positive advanced breast cancer the safety and efficacy of ARX788 compared with lapatinib (Tykerb) and capecitabine (Xeloda).

ZMC-ARX788-211 is a phase 2/3 randomized, multicenter, open-label trial comparing ARX788 with lapatinib and capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer. From 45 centers in China, approximately 440 patients will be randomized 1:1 to receive ARX788 1.5 mg/kg every 3 weeks or lapatinib plus capecitabine until disease progression, intolerable toxicity, or death. All patients included in the study require progression on ≥1 previous lines of HER2 therapy. Progression-free survival will be the primary outcome measure. Investigator-assessed progression-free survival, duration of response, overall survival, safety, immunogenicity, objective response rate, disease control rate, and population pharmacokinetics are considered secondary outcome measures. Two interim analyses will be included in the study.

When 160 patients have completed cycle 4 assessment to detect potential early futility trends, the first interim analysis will be completed. An international phase 2/3 trial of ARX788 is currently being planned.

Source: Hu X, Zhang J, Wang L, et al. A randomized, multicenter, open-label phase II/III study of ARX788 vs Lapatinib and Capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer (ZMC-ARX788-211). Presented at: San Antonio Breast Cancer Symposium, December 8-11, 2020. Abstract PS10-57.

Related Items
Health-Related Quality of Life in Patients with Metastatic Breast Cancer and Brain Metastases Treated with Tucatinib in Combination with Trastuzumab plus Capecitabine
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
NALA Phase 3 Trial Outcomes in Patients Treated with Neratinib or Lapatinib
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
HER2CLIMB-02: A Randomized, Double-Blind, Phase 3 Study of Tucatinib with T-DM1 for the Treatment of Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Final Overall Survival Analysis from the Randomized Phase 3 ExteNET Trial of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Hormone Receptor Status Is Not a Factor in the HER2CLIMB Study of Tucatinib Combination Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Efficacy, Safety, and Tolerability of Tucatinib in Combination with Letrozole and Palbociclib in Patients with HR-Positive, HER2-Positive Metastatic Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Use of Circulating Tumor Cells to Guide Treatment with HER2 Therapy
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Real-World Analysis of Outcomes in Older Women with HER2-Positive Advanced Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Effect of Brain Metastases in Real-World Treatment Patterns and Healthcare Resource Utilization Among HER2-Positive Metastatic Breast Cancer Patients
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Conference Correspondent  published on December 8, 2017 in SABCS Highlights
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: